As of May 27, 2025, Medivolve Inc (MEDV.NE) reports a Net Margin of -49.40%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Medivolve Inc's Net Margin
Over recent years, Medivolve Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -49.40% |
| 2021-12-31 | -7.61% |
| 2020-12-31 | -356.96% |
This fluctuation highlights how Medivolve Inc manages its overall profitability and cost control over time.
Comparing Medivolve Inc's Net Margin to Peers
To better understand Medivolve Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Medivolve Inc (MEDV.NE) | -49.40% |
| Global Cord Blood Corp (CO) | 40.30% |
| Avem Health Partners Inc (FPCG) | 29.77% |
| PharmChem Inc (PCHM) | 22.69% |
| Interpace Biosciences Inc (IDXG) | 14.28% |
| Nova Leap Health Corp (NLH.V) | 5.35% |
Compared to its competitors, Medivolve Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.